Press

  • aside

    Isofol announces that an abstract with new research results has been published for this year’s ASCO congress in Chicago

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American…

    by
  • aside

    Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug…

    by
  • aside

    Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free…

    by
  • aside

    Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based…

    by
  • aside

    Isofol reports successful outcome from the scientific advice with the EMA

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate…

    by
  • aside

    Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with…

    by